Lessons from Biologicals in Asthma for ENT

Rhinology Future Debates Brussels 2017

Several biological therapies, mainly targeting type 2 inflammation, have been shown to be effective in reducing asthma exacerbation, be corticosteroid-sparing, improving lung function and/or improving quality of life in patients with severe asthma. Evidence is accumulating that also in upper airway disease, such as chronic rhinosinusitis with nasal polyps (CRSwNP), these therapies are effective and can reduce nasal polyp size, improve the patients’ Qol and positively impact lower airway outcome parameters.

Panellists

Prof. Peter Hellings, Prof. Claus Bachert, Prof. Wytske Fokkens, Prof. Guy Joos, Prof. Renaud Louis, Prof. Charles Pilette, Prof. Glenis Scadding, Dr. David Price and patient representatives.